FBLG FibroBiologics, Inc.

NASDAQ
$1.41

FibroBiologics, Inc. (FBLG) is expected to report earnings on October 29, 2026, after the market close. The consensus earnings estimate is a loss of $0.63 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +95.8% since its last earnings release on July 31, 2026.

FibroBiologics Beat Consensus Estimates
Friday, July 31, 2026 · 5:34 PM ET
Earnings Date
3rd Quarter, Sep 2026
Oct 29
Thursday · 5:55 PM ET
Earnings Whisper
-
vs ($0.63)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.15

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About FibroBiologics, Inc.

FibroBiologics Inc. is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics Inc. is based in HOUSTON.

Sector

Healthcare

Industry

Biotechnology